A lipid nanoparticle is a formulated fat-based carrier that protects RNA and helps it enter cells. Getting into a cell, releasing usable RNA into the cell fluid and making protein are separate steps, and a particle can succeed at the first without the others.
A typical RNA-delivery lipid nanoparticle combines an ionisable lipid, a phospholipid, cholesterol and a polyethylene glycol lipid around the RNA; the proportions, lipid identities and preparation change behaviour, so the label LNP alone does not name a product. Ionisable lipids change charge with pH. In common designs they are more protonated in an acidic environment and less charged at physiological pH; the extent depends on the lipid and its environment. This can support membrane interactions during endosomal escape, whose performance remains formulation- and cell-dependent (Hou and colleagues, review). Cells usually take particles into endosomes, and messenger RNA is translated by ribosomes in the cytosol, so usable delivery needs the RNA to leave the endosome. Ordinary messenger RNA does not need to enter the nucleus.
Uptake and expression were measured separately in primary human adipocytes, fibroblasts and HeLa cells with six LNP formulations of similar size (54 to 73 nm) carrying eGFP mRNA: total uptake was necessary but not a sufficient predictor of delivery, one formulation gave the highest eGFP expression despite moderate uptake, prolonged uptake impaired endosomal acidification and left mRNA in compartments unproductive for delivery, and early endocytic and recycling compartments had the highest probability of escape (Paramasivam and colleagues). In that study eGFP expression served as a proxy for release; it did not measure the fraction of RNA that escaped.
Where particles go depends on formulation and route. In female BALB/c mice given luciferase-mRNA LNPs by intramuscular, subcutaneous or intravenous injection, some intramuscular particles reached the liver and spleen, smaller particles more than larger ones, bigger particles tended to stay at the injection site, and liver expression was the most prominent; exposure and expression were not linearly related (Di and colleagues). Mouse distribution is not another product's distribution in people, and local injection does not establish local delivery. Readouts answer different questions: particle size, RNA integrity and encapsulated fraction describe the product; a labelled lipid or labelled RNA shows where a label went, not that intact RNA arrived or was released; and protein per identified live cell shows expression. In the mouse study a lipid label (DiR or deuterium-labelled cholesterol) and luciferase activity were measured separately and did not track each other linearly, and every figure needs its denominator (all cells, live cells or expressing cells). Uptake and protein are different fractions: in the six-formulation study the formulation with the highest eGFP expression had only moderate uptake, so a formulation that takes up in more cells can still make protein in fewer. Message and effect also run on separate clocks: in cultured mouse T cells CAR expression from LNP mRNA peaked at 24 hours and fell over the next days (Rurik and colleagues), and the same RNA in particles of different size or by a different route distributed differently, so the same RNA is not the same product.
The cancer relevance is as a carrier of antigen-encoding RNA or of instructions for engineering immune cells. The carrier, where it goes, which cells make protein and what that protein does are different questions; none of these studies is evidence of clinical benefit.
Showing the technology this term belongs to: mRNA and lipid nanoparticle manufacturing.
Shares In vivo CAR-T and the tag delivery-vehicle.
Shares In vivo CAR-T and the tag delivery-vehicle.
Shares In vivo CAR-T and the tag delivery-vehicle.
Shares In vivo CAR-T, Personalised neoantigen (mRNA) vaccines.
Shares mRNA and lipid nanoparticle manufacturing, Personalised neoantigen (mRNA) vaccines.
Shares In vivo CAR-T, Personalised neoantigen (mRNA) vaccines.
Shares RNA-lipoplex, mRNA and lipid nanoparticle manufacturing, Personalised neoantigen (mRNA) vaccines.
Shares In vivo CAR-T, Personalised neoantigen (mRNA) vaccines.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/